- ►pipex.com [PDF] RR Holman, KI Thorne, AJ Farmer, MJ Davies, … - New England Journal of Medicine, 2007 - content.nejm.org From the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and
Metabolism (RRH, KIT, AJF, JFK, SP, JCL) and the Department of Primary Health
Care (AJF), University of Oxford, Oxford; and the Department of Cardiovas- ... Cited by 134 - Related articles - BL Direct - All 12 versions
- ►endojournals.org L Juurinen, A Kotronen, M Graner, H Yki- … - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc Methods: We determined the effect of the PPAR agonist rosiglitazone on liver fat
and directly measured hepatic insulin sensitivity in 14 patients with type 2
diabetes (aged 51 ± 3 yr, body mass index 36.7 ± 1.1 kg/m 2 ), who were ... Cited by 11 - Related articles - BL Direct - All 4 versions
M Davies, F Lavalle-Gonzalez, F Storms, R … - Diabetes Obes Metab, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 8 - Related articles - All 3 versions
M Monami, N Marchionni, E Mannucci - Diabetes research and clinical practice, 2008 - Elsevier A total of 14 RCTs was retrieved and included in the analysis. Long-acting
analogues did not produce any significant improvement of HbA1c, in comparison
with NPH human insulin. When trials with different analogues were analysed ... Cited by 5 - Related articles - All 14 versions
A Woehl, M Evans, AP Tetlow, P McEwan - Cardiovascular Diabetology, 2008 - cardiab.com Exenatide belongs to a new therapeutic class in the treatment of diabetes
(incretin mimetics), allowing glucose-dependent glycaemic control in Type 2
diabetes. Randomised controlled trial data suggest that exenatide is as ... Cited by 4 - Related articles - Cached - All 9 versions
… FG Eliaschewitz, CR Heilmann, DB Muchmore … - Diabetes technology & therapeutics, 2009 - liebertonline.com Julio Rosenstock, MD,1 Freddy G. Eliaschewitz, MD,2 Cory R. Heilmann, Ph.D.,3
Douglas B. Muchmore, MD,4 Risa P. Hayes, Ph.D.,3 and Ruth M. Belin, MD3 ...
Abstract Background: Patients with type 2 diabetes often initiate insulin ... Cited by 3 - Related articles - All 4 versions
FJ Ampudia-Blasco, J Rosenstock - Avances en diabetología, 2008 - sediabetes.org Resumen La diabetes tipo 2 se caracteriza por una resistencia a la insulina y un
deterioro progresivo de la función beta pancreática. Cuando dicha función se
altera, muchos pacientes con diabetes mellitus tipo 2 ne- cesitarán ... Cited by 4 - Related articles - View as HTML - All 6 versions
P Levin - Diabetes, Obesity and Metabolism, 2008 - interscience.wiley.com Diabetes mellitus is a major public health problem, in particular because of
long-term complications affecting essential organs, such as the eyes and
kidneys, which can lead to a reduction in life expectancy and high ... Cited by 2 - Related articles - All 5 versions
S Goykhman, A Drincic, JC Desmangles, M … - Expert Opin. Pharmacother., 2009 - informahealthcare.com Insulin Glargine was the first long-acting insulin analog produced by
recombinant DNA technology, approved for use by the US FDA in April 2000 and by
the European Agency for the Evaluation of Medicinal Products in June, 2000. ... Cited by 2 - Related articles - All 5 versions
MA Elrishi, J Jarvis, K Khunti, MJ Davies - Expert Opin. Drug Metab. Toxicol., 2008 - informahealthcare.com Background: Insulin glargine (Lantus ® ) was the first recombinant-DNA
long-acting insulin analogue to be licensed for use in the treatment of diabetes
mellitus. Objective: This review considers the use of insulin glargine in ... Cited by 1 - Related articles - All 7 versions
